Indoco Remedies Intimates Demise of Non-Executive Director Dr. Anand Nadkarni

Indoco Remedies Limited has formally intimated the stock exchanges regarding the demise of Dr. Anand Nadkarni (DIN: 06881461), Non-Executive Director of the Company, on Friday, 15th May, 2026. The disclosure was made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and was communicated to both the National Stock Exchange of India Limited and the Bombay Stock Exchange Limited.

Regulatory Disclosure Under SEBI Regulation 30

The intimation was filed by Ramanathan Hariharan, Company Secretary & Head Legal of Indoco Remedies, on 15th May, 2026. The filing references SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January, 2026, under which the requisite details of the cessation have been disclosed as Annexure A.

The following details have been provided as required under the applicable regulatory framework:

Parameter:	Details
Name:	Dr. Anand Nadkarni (DIN: 06881461)
Reason for Change:	Demise
Date of Cessation:	15th May, 2026
Brief Profile (Appointment):	Not Applicable
Disclosure of Relationships:	Not Applicable

Company Pays Tribute

Indoco Remedies expressed profound grief over the sudden and unexpected passing of Dr. Anand Nadkarni. The Company noted that his association as a Non-Executive Director had immensely benefitted the organisation, and described his loss as irreparable. All directors and employees of the Company conveyed deep sympathy, sorrow, and condolences to his family.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+0.04%	-1.27%	+18.81%	-0.43%	-16.84%	-42.51%

Indoco Remedies has formally completed the transfer of its ophthalmic business division to Sunways (India) Private Limited as a going concern on a slump sale basis, effective May 18, 2026. The company disclosed this development to the stock exchanges in continuation of its earlier intimation dated April 30, 2026, which had announced the approval and execution of the Agreement to Transfer Business (ATB).

Business Transfer Details

The transfer encompasses the company's Ophthalmic Division across a defined set of territories. All conditions precedent stipulated under the ATB have been fulfilled, enabling the completion of the transaction on the stated date. The following table summarises the key parameters of the transaction:

Parameter:	Details
Transaction Type:	Slump sale (going concern basis)
Transferor:	Indoco Remedies Limited
Transferee:	Sunways (India) Private Limited
Division Transferred:	Ophthalmic Division
Completion Date:	May 18, 2026
Initial Disclosure Date:	April 30, 2026

Territories Covered

The business transfer covers the ophthalmic division's operations across the following territories:

India
West Africa: Benin, Burkina Faso, Ivory Coast, Mali, Niger, Mauritania, Senegal
Central Africa: Cameroon, Congo, Gabon
East & Southern Africa: Kenya, Tanzania, Zambia, Zimbabwe, Botswana, Namibia

Regulatory Disclosure

The intimation regarding the completion of the business transfer was submitted to both the National Stock Exchange of India Limited and the Bombay Stock Exchange Limited under Regulation 30. The disclosure was signed by Ramanathan Hariharan, Company Secretary & Head Legal of Indoco Remedies Limited, on May 18, 2026.